# Cumulative Index 1990

## Volume 19

| | |
|---|---|
| *March* | METABOLIC BONE DISEASE, Part II, pages 1–210 |
| *June* | LIPID DISORDERS, pages 211–468 |
| *September* | THYROID CARCINOMA, pages 469–766 |
| *December* | RENAL STONES, pages 767–965 |

*Note:* Page numbers of article and issue titles are in **boldface** type.


Absorption of oxalate, 855–860
Acid phosphatase, tartrate-resistant, and bone resorption, 12
Acid-base physiology, and renal tubular acidosis, 869–871
Acidosis, and parenteral nutrition-related bone disease, 116–117
  renal tubular, **869–887**
    acid-base physiology, 869–871
    and bone disease, 881–882
    diagnosis and treatment, 882–884
    distal tubule, 871
    etiology and clinical features, 877–879
      hyperkalemic distal RTA (type 4), 879
      hypokalemic distal RTA (type 1), 877
      proximal RTA (type 2), 877
    nephrocalcinosis, 882
    nephrolithiasis, 879–881
    therapy, 884–885
    type 1 (distal RTA), 872–875
      pathogenesis, 872–876
        back-diffusion, 874
        carbonic anhydrase deficiency, 875
        rate-dependent, 875
        voltage-dependent, 874–875
      secretory, 873–874
    type 2 (proximal RTA), pathogenesis, 875–876
    type 4, pathogenesis, 876
      aldosterone resistance state, 876
Adenine phosphoribosyltransferase (APRT) deficiency, and urolithiasis, 830
Adolescents, neck mass assessment, 658–660
Age, and bone GLA-protein, 3–4
  and TC, TG, and LP distribution in children, 405–412
  and thyrotoxicosis, 603–604
  and papillary thyroid carcinoma, 546, 553–554
Alcohol, and acquired hyperlipidemia, 265–266
  and circulating lipoproteins, 335–336
  and TC, TG, and LP distribution in children, 415
Aldosterone resistance, and renal tubular acidosis, 876
Alkaline phosphatase, in renal osteodystrophy, 72
  serum, and bone formation, 2–3
Aluminum, and parenteral nutrition-related bone disease, 119–125
  renal disease, 67–69, 70, 119–123
  toxicity, 119
Amyloidosis, cutaneous lichen, and MEN 2A, 620–621
Anaplastic thyroid carcinoma, 637–642
  and radioiodine therapy, 705
Anatomy, of medullary thyroid carcinoma, 613–614
Angiography, of thyroid carcinoma, 540
Antibiotics for secondary urolithiasis, 910–911
Apo A-containing lipoproteins, 223–224
  and atherogenesis, 225–226
Apo B-containing lipoprotein pathophysiology, 230–237
Apo B-100–containing lipoproteins, 218–220
  and atherogenesis, 221–223

Apoproteins in lipoproteins, 213–216
Arthritis in Paget's disease of bone, 181
Arthropathy, dialysis, 85–86
Artifacts, in radioiodine therapy, 697–698
Ascorbic acid, and hyperoxaluria, 860
Atherogenesis, and apo A-I lipoproteins, 226–227
  and apo B-100–containing lipoproteins, 221–223
  and exogenous lipid transport, 217–218
Atherosclerosis, in children, 400–401
  and glucose intolerance, 369–371

Back-diffusion renal tubular acidosis, 874
Back pain, in Paget's disease of bone, 178–179
Beta-receptor blocking agents, and bone loss, 55
Bile acid sequestrants, 348–350
Biochemical markers of bone turnover, **1–18**
  bone formation, 2–9
    alkaline phosphatase, 2–3
    bone GLA-protein, 3–8
    other bone proteins, 9
    procollagen I extension peptides, 8–9
  bone resorption, 9–14
    collagen pyridinium crosslinks, 13–14
    gamma-carboxyglutamic acid, 12–13
    hydroxylysine glycoside, 11–12
    hydroxyproline, 9–11
    tartrate-resistant acid phosphatase, 12
Biopsy, of bone, in hyperparathyroid bone disease, 74
    in low-turnover bone disease, 82
    in mild uremic bone disease, 83–84
    in mixed uremic bone disease, 81
    in osteomalacia, 78
  of neck mass in childhood thyroid cancer, 660
Bladder stones, 932
Blood, and radioiodine therapy, 702–704
Bone disease, metabolic, **1–210**
  biochemical markers of bone turnover, **1–18**
    bone formation, 2–9
    bone resorption, 9–14
  corticosteroid-induced osteoporosis, **95–111**
    epidemiology and natural history, 96–97
    glucocorticoids and calcium homeostasis, 100–102
    pathogenesis, 97–100
    treatment, 102–106
  heritable metabolic and dysplastic diseases, **133–172**
    carbonic anhydrase II deficiency, 153–156
    fibrodysplasia ossificans progressiva, 162–167
    hypophosphatasia, 134–142
    osteogenesis imperfecta, 142–146
    osteopetrosis, 146–153
    progressive diaphyseal dysplasia (Camurati-Engelmann disease), 158–162
    pycnodysostosis, 156–158
  hyperparathyroidism, primary, **19–34**
    bone densitometry, 23–24
    "classic" disease, 21–23
    clinical profile, 20
    histomorphometry of bone, 25–31
    normal adult bone remodeling, 24–25
  Paget's disease of bone, **175–202**
    clinical manifestations, 178–181
    etiology, 176–177
    history, 175–176
    laboratory data, 183–187
    patient distribution, 177–178
    radiology, 182–183
    treatment, 187–200
    tumors, 200
  and parenteral nutrition, **113–131**
    aluminum effects, 119–125
    causes of, 115–119
    pre-existing skeletal disease, 114
  renal tubular acidosis, 881–882
  renal osteodystrophy, **65–93**
    aluminum metabolism, 67–69
    biochemical tests, 69–74
    dialysis arthropathy and erosive spondyloarthropathy, 85–86
    hyperparathyroid bone disease, 74–77
    low-turnover bone disease, 82–83
    mild uremic bone disease, 83–84
    mineral metabolism, 66–67
    mixed uremic bone disease, 81–82
    osteomalacia, 78–81
    after renal transplantation, 84–85
  thyroid hormones and mineral metabolism, **35–63**
    bone and mineral metabolism, 50–51
    calcitropic hormones, 48–50
    calcium homeostasis in thyroid disorders, 35–37, 45–46
    clinical aspects, 52–56
    phosphate homeostasis, 47–48
    skeleton defects, 37–45
Bone gla protein (BGP). See *GLA-protein.*
Bone marrow, and radioiodine therapy, 702–704
Bone matrix organization disorders, bone GLA-protein in, 7–8
Bone pain, in Paget's disease of bone, 180–181
Bone remodeling. See *Remodeling.*
Bone resorption and turnover, in corticosteroid-induced osteoporosis, 100, 105–106

C-cell abnormalities, in medullary thyroid carcinoma, 617–618
*C-erbB*, in thyroid carcinomas, 486
*C-myc/c-fos*, in thyroid carcinomas, 484–485
*C-ras*, in thyroid carcinomas, 485–486
Calcification, and renal tubular acidosis, 882
Calcitonin, in medullary thyroid carcinoma, gene expression, 614–616
persistent elevation, 629–630
tumor marker, 619
in thyroid disorders, 50
Calcitropic hormones, 48–50
calcitonin, 50
parathyroid hormone, 48
vitamin D metabolites, 48–50
Calcium, homeostasis, in corticosteroid-induced osteoporosis, 100–102
in thyroid disorders, 35–37, 45–46
intestinal absorption, 45
renal calcium excretion, 46
serum calcium, 45–46
and parenteral nutrition-related bone disease, 115
in renal osteodystrophy, 71
supplementation, in corticosteroid-induced osteoporosis, 104–105
renal stones, dietary factors, 813–814
refractory, clinical evaluation, 783–787
Calcium oxalate stones, 805–816
dietary factors, 805–807, 812–813
in hyperuricosuria, 815–816
idiopathic, **937–947**
hypercalciuria, 939–940
hyperoxaluria, 940–941
hyperuricosuria, 941–942
inhibitors, 942–944
pH, 942
urine volume, 938–939
Camurati-Engelmann disease. See *Progressive diaphyseal dysplasia.*
Carbohydrates, and TC, TG, and LP distribution in children, 414–415
Carbonic anhydrase deficiency, and renal tubular acidosis, 875
Cardiovascular disease, in children, 399, 440
in dyslipoproteinemic children, 444
and glucose intolerance, 369–370
lipids and lipoproteins in, 370–371
in women, 384–395
Central nervous system metastases, 707–708
Chemotherapy, for thyroid carcinoma, 733–734
Children, bone GLA-protein in, 8
dyslipoproteinemia in, **399–449**
adult cardiovascular disease starting in childhood, 399
control during childhood, 399–404
atherosclerotic lesions, 401–402
high CV risk lifestyles, 404
lipoprotein patterns, 401–405
TC and LP in children, and CHD in adults, 402–404
CVD reduction, 440
diagnosis, 425–428
family information and counseling, 427–428
sequential elements, 425–427
future studies, 440–441
management, 437–440
familial hypercholesterolemia, 437–440
hypertriglyceridemia, 438–440
screening programs, 418–425
alternative strategies, 420–422
criteria, 418
recommendations, 422–425
TC, TG, and LP distribution, 405–418
age, 405–412
cigarette smoking, 419
familial aggregation, 412–413
gender, pubertal development, and sex hormones, 413–414
medications, 418
nutrients, 414–415
physical activity, adiposity, and insulin, 415–417
population surveys and methods of measurement, 405
race, 413
treatment, 429–437
diet, 433–439
medication, 435–427
physical activity and cigarette smoking, 435
thyroid cancer, **649–662**
clinical presentation, 650
etiology, 652–654
genetics, 653
radiation, 652–653
thyroiditis, 653–654
incidence, 650
medullary thyroid carcinoma, 657–658
neck mass assessment, 658–660
prognosis, 655–656
therapy, 654–655
iodine ablation, 654–655
replacement therapy vs. TSH suppression, 655
surgery, 654
Cholesterol, in children, and CHD in adults, 402–404
distribution, correlates, and determinants of, 405–418
and coronary heart disease, **279–297**
angiographic studies, 290–292
clinical trials of LDL cholesterol lowering, 284–290
adverse effects, 292–294
life expectancy, 290
myocardial infarction, 289

Cholesterol *(Continued)*
older men, 288–289
risk reduction, 284–288
triglyceride elevation, 289–290
women, 289
low-density lipoproteins, 280–283
regression studies in animals, 290–292
dietary, and circulating lipoproteins, 326–327
in elderly, 452–454
in lipoproteins, 211–212
in women, 384–395
Chromosomal ploidy analysis, 474–475
Chylomicronemia, acquired hyperlipidemia, 270–272
inherited disorders, 240–242
Cigarette smoking, and dyslipoproteinemia in children, 417, 425
Collagen pyridinium crosslinks, and bone resorption, 13–14
Computed tomography, of thyroid carcinoma, 538
Coronary artery disease. high-density lipoproteins and triglycerides, **299–309**
epidemiology, 299–302
inherited disorders, 302–303
intervention studies, 303–305
Coronary heart disease, and diet. See *Diet, lipids, and coronary heart disease.*
and lower cholesterol levels. See *Cholesterol, and coronary heart disease.*
in pregnancy, 389–390
Corticosteroids, and osteoporosis. See *Osteoporosis, corticosteroid-induced.*
Crystals, and renal stones, 768–771
Cystic disorders, secondary urolithiasis, 913–914
Cystine stones, 797–798
Cystinuria, **889–907**
clinical features, 896–898
diagnosis, 894–895
genetics, 891–894
intestinal transport defects, 890–891
renal transport defects, 889–890
treatment, 898–902

Decision analytic model, of radioiodine therapy, 747–748
Densitometry of bone, in primary hyperparathyroidism, 23–24
Dextrose, in parenteral nutrition-related bone disease, 117
Diabetes mellitus, and acquired hyperlipidemia, 261–265
and dyslipoproteinemia, **361–380**
lipoprotein metabolism, 361–365
management, 372–375
pathophysiology, 365–371
atherosclerosis risk, 371
glucose intolerance and cardiovascular disease, 369–370
insulin-dependent diabetes, 365–367
lipids and lipoproteins in cardiovascular disease, 370–371
non-insulin-dependent diabetes, 367–368
Dialysis arthropathy, chronic, 85–86
Diet, cholesterol lowering in elderly, 460
and coronary heart disease, 322–326
experimental studies, 322
intervention studies, 325–326
population studies, 322–324
for dyslipoproteinemia in children, 429–435
guidelines for diet, 337–338
postprandial lipemia, 336–337
practical approach, 338–339
and lipids, and coronary heart disease, **321–345**
and circulating lipoproteins, 326–336
alcohol, 335–336
dietary cholesterol, 326–327
fats, 328–334
fiber, 334–335
low-iodine, 690–691
in pathogenesis and therapy of nephrolithiasis, **805–820**
calcium, and calcium stone formation, 813–814
calcium oxalate nephrolithiasis, 805–807
oxalate, and enteric hyperoxaluria, 812–813
epidemiologic studies, 806–807, 816–817
fluid intake, and recurrent nephrolithiasis, 814
in hyperuricosuria, 815–816
protein effects, 807–808
and hypercalciuria, 808–810
sodium, and hypercalciuria, 813–812
Dimercaptosuccinic acid, 535
Diuretics, and acquired hyperlipidemia, 268–269
DNA ploidy, in papillary thyroid carcinoma, 561–563
Dosimetric studies, in radioiodine therapy, 695–697
Drugs, and acquired hyperlipidemia, 268–270
cholesterol lowering in elderly, 460–461
for dyslipoproteinemia, 345–360
and secondary urolithiasis, 914–916
Dysbetalipoproteinemia, 244–245
Dyslipoproteinemia, in children, **399–449**
adult disease starting in childhood, 399
cholesterol, triglyceride, and lipoprotein distribution, 405–418
control during childhood, 399–404
CVD reduction, 440

diagnosis, 425–428
future studies, 440–441
management, 439–440
screening programs, 418–425
treatment, 429–437
detection and evaluation, **311–320**
hypercholesterolemia, 312–317
screening for triglycerides, 318–319
and diabetes, **361–380**
lipoprotein metabolism, 361–365
management, 372–375
pathophysiology, 365–371
atherosclerotic risk, 371
glucose intolerance and cardiovascular disease, 369–370
insulin-dependent diabetes mellitus, 365–367
lipids and lipoproteins in cardiovascular disease, 370–371
non-insulin-dependent diabetes mellitus, 367–368
drug treatment, **345–360**
availability in US, 347–348
bile acid sequestrants, 348–350
combination therapy, 357–358
fibric acid derivatives, 355–356
guidelines, 346–347
HMG CoA reductase inhibitors, 353–355
nicotinic acid, 351–353
probucol, 356–357
in elderly, **451–462**
background, 452–457
patient evaluation and treatment, 457–461
secondary. See *Hyperlipidemia, acquired.*
in women, **381–399**
cardiovascular risk and cholesterol/lipoproteins, 384–395
coronary heart disease, 387–388
estrogens and progestogens, 389–390
hormonal contraceptives, 391
in menopause, 391–393
hormone replacement, 392–394
in menstrual cycle, 384
oral contraceptive risk, 389–391
in pregnancy, 384–385
therapeutic use of hormones, 394–395
epidemiology of heart disease, 381–384
Dysplasias. See *Heritable metabolic and dysplastic bone diseases.*

Elderly, dyslipoproteinemia in, **451–462**
background, 452–457
cholesterol as risk factor, 452–453
screening, 455–456
studies, 453–454
national recommendations, 456–457
postmortem studies, 453
specific issues, 454
patient evaluation and treatment, 457–461
dietary therapy, 460
drug therapy, 461–464
electrophoretic typing, 459
hypercholesterolemia, 457–460
Endocrine disorders, and acquired hyperlipidemia, 270
Environment, and renal stones, 779–780
Epidemiology, cholesterol levels and coronary heart disease, 282–283
corticosteroid-induced osteoporosis, 96–97
dietary factors in nephrolithiasis, 806–807
follicular thyroid carcinoma, 577–578
heart disease in women, 381–384
high-density lipoprotein and triglycerides in coronary heart disease, 202–302
radiation-induced thyroid neoplasms, 496
Epidermal growth factor, in normal thyroid, 482
Estrogens, cardiovascular risk and cholesterol/lipoproteins, 389–390
Ethylene glycol, and hyperoxaluria, 860
Etiology, of carbonic anhydrase II deficiency, 155
of fibrodysplasia ossificans progressiva, 166
of osteopetrosis, 151–152
of Paget's disease of bone, 176–177
of progressive diaphyseal dysplasia, 160–162
of pycnodysostosis, 157–158
of renal tubular acidosis, 877–879
Excretion, of oxalate, 855–860

Family counseling, dyslipoproteinemia in children, 427–428
Family studies, dyslipoproteinemic children, 403
lipid and lipoprotein aggregation, 412–413
probands with early CHD, 403–404
Fats, dietary, and circulating lipoproteins, 324–330
and TC, TG, and LP distribution in children, 414–415
diet modifications, 430–433
Fertility, and radioiodine therapy, 710–711
Fiber, dietary, and circulating lipoproteins, 334–335
Fibric acid derivatives, 355–356
Fibrodysplasia ossificans progressiva, 162–167
clinical presentation, 162–163
etiology and pathogenesis, 166
histopathology, 165–166
laboratory findings, 165

Fibrodysplasia ossificans progressiva
*(Continued)*
prognosis, 167
radiology, 163–165
treatment, 166
Fluid intake in recurrent nephrolithiasis, 814
Follicular thyroid carcinoma, **577–583**
clinical features, 578
diagnosis, 580
epidemiology and pathogenesis, 577–578
follow-up evaluation, 582
oncogenes in, 484–486
pathology and cytopathology, 578–579
prognostic factors, 582–583
radioiodine therapy, 686–688
surgery for, 666–670
therapy, 580–582
Foreign bodies, and renal stones, 916
Fractures, in Paget's disease of bone, 193–196

Gallium, 536
Gamma-carboxyglutamic acid, and bone resorption, 12–13
Gastrointestinal tract, enteric hyperoxaluria, 862–863
oxalate absorption, transport, and excretion, 855
and radioiodine therapy, 705
Gender, and TC, TG, and LP distribution in children, 413–414
Genetics, of childhood thyroid cancer, 653
of cystinuria, 891–894
of MEN type 2, 621–623
of radioiodine therapy, 708–709
GLA-protein, and bone formation, 3–8
aging effects, 3–4
in bone turnover disorders, 6–7
in children, 8
matrix organization disorders, 7–8
in renal osteodystrophy, 72–73
significance of circulating levels, 8
in vertebral osteoporosis, 5
Glucocorticoids. See *Osteoporosis, corticosteroid-induced.*
Glucose, and cardiovascular/atherosclerotic disease, 369–370
Gonads, and radioiodine therapy, 708
Growth, hypothyroid retardation, 52
Growth factors. See *Oncogenes and growth factors.*

HDL, low syndromes, inherited disorders, 248–249
pathophysiology, 238–239
Head and neck, radiation and thyroid cancer, 501–504
Heritable metabolic and dysplastic bone diseases, **133–172**
carbonic anhydrase II deficiency, 153–156
hypophosphatasia, 134–142
biochemical/genetic defect, 141
clinical presentation, 134–136
histopathology, 140
inheritance, 140–141
laboratory data, 138–139
prenatal diagnosis, 142
prognosis, 142
radiology, 136–138
treatment, 141–142
osteogenesis imperfecta, 142–146
clinical presentation, 143–144
histopathology, 145
laboratory tests, 145
pathogenesis, 145–146
radiology, 144–145
treatment, 146
osteopetrosis, 146–153
clinical presentation, 147–148
histopathology, 151
laboratory data, 150
pathogenesis and etiology, 151–152
radiology, 149–150
treatment, 152–153
progressive diaphyseal dysplasia (Camurati-Engelmann disease), 158–162
clinical presentation, 158–159
etiology and pathogenesis, 160–162
histopathology, 160
laboratory data, 159–160
radiology, 159
treatment, 162
pycnodysostosis, 156–158
Histomorphometry of bone, in primary hyperparathyroidism, 25–31
Histopathology, of carbonic anhydrase II deficiency, 154–155
of fibrodysplasia ossificans progressiva, 165–166
of osteogenesis imperfecta, 145
of osteopetrosis, 151
of progressive diaphyseal dysplasia, 160
of pycnodysostosis, 157
HMG CoA reductase inhibitors, 353–355
Hürthle cell carcinoma of thyroid, **583–587**
clinical presentation, 584
pathology, 584–585
prognosis, 586–587
treatment, 585–586
Hydroxylysine glycoside, 11–12
Hydroxyproline, and bone resorption, 9–11
in bone disease, 10–11
metabolism, 9–10
Hypercalcemia, and urinary calculi, **839–849**
hyperparathyroidism, 839–843
calculus formation, 840–841
differential diagnosis, 841–843

treatment, 843
hypervitaminosis D, 845
idiopathic, of infancy, 846–847
immobilization-induced, and hypercalciuria, 845–846
and malignant tumors, 846
milk-alkali syndrome, 845
multiple myeloma, 846
sarcoidosis, 844–845
Hypercalciuria, and calcium oxalate urolithiasis, 939–940
calcium and phosphorus in parenteral nutrition, 115
and diet, protein, 808–810
sodium, 810–812
and immobilization-induced hypercalcemia, 845–846
and parenteral nutrition-related bone disease, 115–118
calcium and phosphorus, 115
cyclic vs. continuous administration of PN, 115–116
dextrose and insulin, 117
protein and acidosis, 116–117
sodium, 118
risk factor for renal stones, 787–789
Hypercholesterolemia, 312–317
combination drug therapy, 357
in elderly, 457–460
familial, 437–438
Hyperchylomicronemia in children, 438–439
Hyperkalemia, and renal tubular acidosis, 879
Hyperlipidemia, acquired, **255–279**
causes, 260–270
alcohol, 267–268
diabetes mellitus, 261–265
drugs, 268–270
hypothyroidism, 265
liver disease, 268
nephrotic syndrome, 266–267
physiology of lipoprotein transport, 260–261
renal failure, 266
renal transplantation, 267
chylomicronemia syndrome, 270–272
clinical presentation and diagnosis, 271
definition, 259
management, 272–273
significance, 259–260
inherited. See *Inherited disorders.*
Hyperoxaluric syndromes, **851–867**
and calcium oxalate urolithiasis, 940–941
dietary factors, 812–813
hyperoxalurias, 860–863
endogenous oxalate precursors, 860
exogenous, 862–863
modest, 863
primary, type I, 861
type 2, 861–862
pyridoxine deficiency, 860–861
oxalate, absorption, transport, and excretion, 855–860
gastrointestinal, 855
mitochondria, 859
red blood cells, 859–860
renal, 856–858
clearance, 856–858
transport, 856
in biologic fluids, 851–853
plasma, 853
urine, 852–853
biosynthesis, 853–854
Hyperparathyroidism, primary, **19–34**
bone densitometry, 23–24
bone disease, 21–23
and renal osteodystrophy, 74–77
clinical profile, 20
histomorphometry of bone, 25–31
normal adult bone remodeling, 24–25
and renal stones, 839–843
calculus formation, 840–841
differential diagnosis, 841–843
treatment, 843
Hyperthyroidism, bone disease, 52–54
cortical bone, 41–42
hypercalcemia of, 52
subclinical bone loss, 54
trabecular bone, 39–41
Hypertriglyceridemia, in children, 438–439
Hyperuricosuria, and calcium oxalate urolithiasis, 941–942
dietary factors, 815–816
and renal stones, 791–792
Hypervitaminosis D, and renal stones, 845
Hypocitraturia, and renal stones, 792–793
Hypokalemia, and renal tubular acidosis, 877
Hypothyroidism, and acquired hyperlipidemia, 265
cortical bone, 41–42
growth retardation, 52
replacement therapy, 54–55
trabecular bone, 39–41
Hypoxanthine phosphoribosyltransferase (HPRT) deficiency, and urolithiasis, 829–830

Imaging tests for thyroid carcinoma, 475–476, **523–543**, 730–731
angiography, 540
computed tomography, 538
dimercaptosuccinic acid, 535
gallium, 536
iodine scanning, 530–533
magnetic resonance imaging, 538
meta-iodobenzylguanidine, 533
nuclear angiography, 536

Imaging tests for thyroid carcinoma
*(Continued)*
radiography, 538–540
$^{99m}$technetium, 523–530
$^{201}$thallium, 534
thermography, 540–541
tomography, 535–536
ultrasound, 536–537
xeroradiography, 540
x-ray fluorescent scanning, 537–538
Immobilization, and hypercalcemia, 845–846
Infancy, idiopathic hypercalcemia, 846–847
Infection stones, 798–799, 909–911
pathophysiology, 909–910
treatment, 910–911
medical, 910–911
antibiotics, 910–911
stone solvents, 911
urease inhibitors, 911
surgical, 910
Inherited disorders of lipid transport, **229–257**
clinical syndromes, 240–249
chylomicronemia, 240–242
dysbetalipoproteinemia, 244–245
high-density lipoprotein and triglycerides in
coronary heart disease, 302–303
LDL hyperlipoproteinemia, 244–246
low HDL syndromes, 248–249
low LDL syndromes, 246–248
VLDL hyperlipoproteinemia, 242–243
pathophysiology, 230–239
apo B-containing lipoproteins, 230–237
HDL, 238–239
Lp(A), 238
Insulin, in parenteral nutrition-related bone disease, 117
and TC, TG, and LP distribution in children, 415–417
Insulinlike growth factors, in normal thyroid, 481
Intestine, calcium absorption, in corticosteroid-induced osteoporosis, 100–101
in thyroid disorders, 45
phosphate absorption, 47
transport defects, in cystinuria, 890–891
Iodine scanning, of thyroid carcinoma, 530–533
See also *Radioactive iodine.*

Kidney, aluminum-associated disease, 119–123
stones, **767**
calcium oxalate urolithiasis, idiopathic, **937–965**
hypercalciuria, 939–940
hyperoxaluria, 940–941
hyperuricosuria, 941–942
inhibitors, 942–9444
pH, 942
urine volume, 938–939
clinical and laboratory evaluation, **773–803**
clinical evaluation, 779
composition of stones, 775–779
cystine stone formation, 797–798
environment, 779–780
infected renal stones, 798–799
inhibitors of urinary stone formation, 793–794
initial risk factor, 780–781
radiolucent or uric acid stone formation, 796–797
recurrent stone formers, 781–783
refractory calcium stone formation, 783–787
risk factors, 787–793
tubular function, 794–796
cystinuria, **889–907**
clinical features, 896–898
diagnosis, 894–895
genetics, 891–894
intestinal transport defects, 890–891
renal transport defects, 889–890
treatment, 898–902
diet role in pathogenesis and therapy, **805–820**
calcium, and calcium stone formation, 813–814
in calcium oxalate nephrolithiasis, 805–807
dietary modifications, 816–817
fluid intake, and recurrent nephrolithiasis, 814
in hyperuricosuria, 815–816
oxalate, and calcium oxalate nephrolithiasis and enteric hyperoxaluria, 812–813
protein effects in clinical studies, 807–808
protein loading, and hypercalciuria, 808–810
sodium, and hypercalciuria, 810–812
hypercalcemic states, **839–849**
hyperparathyroidism, 839–843
hypervitaminosis D, 845
idiopathic, of infancy, 846–847
immobilization-induced, and hypercalciuria, 845–846
and malignant tumors, 846
and malignant tumors, 846
milk-alkali syndrome, 845
multiple myeloma, 846
sarcoidosis, 844–845
hyperoxaluric syndromes, **851–867**
hyperoxalurias, 860–863
oxalate absorption, transport, and excretion, 855–860
oxalate in biologic fluids, 851–853

oxalic acid biosynthesis, 853–854
and purine metabolism, **821–838**
defects in uric acid metabolism, 829–931
degradation to uric acid, 824–826
diagnosis of uric acid renal stones, 831–832
medical treatment, 832–834
purine de novo synthesis, 823–824
risk factors, 827–829
salvage pathway, 824
uric acid elimination and metabolism, 822, 826–827
renal tubular acidosis, **869–887**
acid-base physiology, 869–871
and bone disease, 881–882
diagnosis and treatment, 882–884
distal tubule, 871
etiology and clinical features, 877–879
nephrocalcinosis, 882
nephrolithiasis, 879–881
pathogenesis, 872–876
therapy, 884–885
secondary urolithiasis, **909–918**
cystic disorders, 913–914
drug-induced, 914–916
foreign bodies, 916
infection stones, 909–911
structural abnormalities, 911–913
solutions and solute, **767–772**
crystal formation, 768–769
crystal retention, 769–770
modifiers of crystal formation, 770–771
saturation states, 767–768
surgery, **919–935**
background, 919–924
clinical factors, 924–925
indications for stone removal, 924
parameters affecting treatment, 925–934
in thyroid disorders, 46–48
calcium excretion, 46
phosphorus excretion and handling, 47–48
See also *Renal osteodystrophy*.

Laxatives, and radioiodine therapy, 692
LDL hyperlipoproteinemia, 245–246
low syndromes, inherited disorders, 246–248
Lesch-Nyhan syndrome, and urolithiasis, 829–830
Leukemia, and radioiodine therapy, 746–747
Life expectancy, and cholesterol levels, 290
Lipemia, postprandial, 336–337

Lipid disorders, **211–468**
acquired hyperlipidemia, **259–278**
causes of, 260–270
chylomicronemia syndrome, 270–272
clinical presentation and diagnosis, 272
definition, 259
management, 272–273
significance, 259–260
cholesterol levels and coronary heart disease, **279–297**
adverse effects, 292–294
clinical trials of lowering low-density lipoproteins, 284–290
low-density lipoproteins, 280–283
regression studies in animals and human angiographic studies, 290–292
diet, lipids, and coronary heart disease, **321–345**
diet and CHD, 322–326
diet and circulating lipoproteins, 326–336
diet-heart studies, 336–339
dyslipoproteinemia, in children, **399–449**
adult disease starting in childhood, 399
CVD reduction, 440
diagnosis, 425–428
distribution of cholesterol, triglycerides, LP, 405–418
future studies, 440–441
management, 437–440
rationale for control, 399–404
screening programs, 418–425
therapy, 429–437
detection and evaluation, **311–320**
hypercholesterolemia, 312–317
screening for triglycerides, 318–319
and diabetes, **361–379**
lipoprotein metabolism, 361–365
management, 372–375
pathophysiology, 365–371
drug treatment, **345–360**
availability in US, 347–348
bile acid sequestrants, 348–350
combination therapy, 357–358
fibric acid derivatives, 355–356
guidelines, 346–347
HMG CoA reductase inhibitors, 353–355
nicotinic acid, 350–353
probucol, 356–357
in elderly, **451–462**
background, 452–457
patient evaluation and treatment, 457–461
in women, **381–399**
epidemiology of heart disease, 381–384

Lipid disorders *(Continued)*
in menstrual cycle, pregnancy, and menopause, 384–395
high-density lipoprotein and triglycerides in coronary heart disease, **299–309**
epidemiologic studies, 299–302
inherited disorders, 302–303
intervention studies, 303–305
inherited disorders, **229–257**
clinical syndromes, 240–245
pathophysiology, 230–239
lipoprotein physiology, and atherogenesis, **211–228**
lipoprotein composition, 211–216
transport, endogenous lipids, 218–227
exogenous lipids, 216–218
Lipoprotein lipase deficiency, 438–439
Lipoproteins, apo B-containing. See *Apo B-containing lipoproteins.*
in children, 401–402
and CHD in adults, 402–404
distribution, correlates, and determinants of, 405–418
in diabetes, insulin-dependent, 365–367
metabolism, 361–365
non-insulin-dependent, 367–368
diet effects. See *Diet, lipids, and coronary heart disease.*
high-density, and coronary artery disease, **299–309**
epidemiology, 299–302
inherited disorders, 302–303
intervention studies, 303–305
low-density, and coronary heart disease, 280–290
clinical trials, 284–290
elevated levels, 280–283
physiology, and atherosclerosis, **211–228**
lipoprotein composition, 211–216
apoproteins, 213–216
cholesterol, 211–212
phospholipids, 212
triglycerides, 211
transport of lipids, endogenous, 218–227
apo A-containing lipoproteins, 223–226
apo B-100–containing lipoproteins, 218–221
and atherogenesis, 221–223, 226–227
exogenous, 216–218
and atherogenesis, 217–218
Lithium, and radioiodine therapy, 691–692
Liver disease, and acquired hyperlipidemia, 268
Low-turnover bone disease, 82–83
Lp(a), inherited disorders of, 236
Lymph nodes, in surgery for thyroid carcinoma, 670–671
Lymphomas, surgery for, 672–673
of thyroid, 642–645
etiology, 644
immunohistochemistry, 643–644
pathology, 642–643
prognosis and treatment, 645

Magnetic resonance imaging, of thyroid carcinoma, 538
Marrow transplantation, in osteopetrosis, 152–153
Medication, and dyslipoproteinemia in children, 418, 435–437
Medullary thyroid carcinoma, **613–635**
anatomy and histology, 613–614
in children, 657–658
clinical course after thyroidectomy, 627–630
clinical syndromes, 618–621
cutaneous lichen amyloidosis, 620–621
MEN 2A, 619
pheochromocytoma, 620
single nodule evaluation, 619
sporadic, 618–619
CT as tumor marker, 619
CT gene expression, 614–616
in cells outside thyroid, 616
gene products, 614–616
other tumor markers, 616
regulation of production and secretion, 616
genetics of MEN type 2, 621–623
molecular mechanisms for development, 623–624
oncogenes, in, 487
pathology, 617–618
C cell abnormalities, 617–618
hereditary, 617
sporadic, 617
progress in, 472–473
screening for MEN 2A and 2B, 624–626
surgical management, 626–627, 671–672
hereditary, 626–627
sporadic, 626
thyroidectomy, 627
MEN 2A, 619
and 2B, screening tests, 624–626
and cutaneous lichen amyloidosis, 620–621
pheochromocytoma, 620, 625–626
MEN 2B, 621
Men, older, cholesterol levels, and coronary heart disease, 288–289
Menopause, cardiovascular risk, 391–392
hormone replacement, 392–396
Menstrual cycle, cardiovascular risk and cholesterol/lipoproteins, 384
Meta-iodobenzylguanidine, 533

Metastases, of follicular thyroid carcinoma, 581
of papillary thyroid carcinoma, distant, 551–552, 555
postoperative nodes, 550–551
radioiodine effects. See *Radioiodine therapy, of metastatic thyroid cancer.*
and thyrotoxicosis, 599, 605–607
Methoxyflurane, and hyperoxaluria, 860
Mild uremic bone disease, 83–84
Milk-alkali syndrome, and renal stones, 845
Mineral metabolism, in thyroid disorders, 50–51
in renal failure, 66–67
Mitochondria, oxalate binding, 859
Mixed uremic bone disease, 812
Mortality in papillary thyroid carcinoma, 553
Multiple myeloma, and renal stones, 846
Myocardial infarction, cholesterol levels, and coronary heart disease, 289

Neck mass assessment in children and adolescents, 658–660
Needle aspiration, in thyroid carcinoma, 472, 726–729
Neoplasms, and renal stones, 846
Nephrolithiasis. See *Kidney stones.*
Nephrotic syndrome, 266–267
Nicotinic acid, for dyslipoproteinemia, 350–353
Nodules, thyroid. See *Surgery, pathology of thyroid nodules.*
Nuclear angiography, of thyroid carcinoma, 536
Nutrition, parenteral, and metabolic bone disease, **113–131**
aluminum effects, 119–125
HPN bone disease, 123–125
renal disease, 119–123
causes of, 115–119
aluminum toxicity, 119
calcium, phosphorus, and hypercalciuria, 115
cyclic vs. continuous administration, and hypercalciuria, 115–116
dextrose, insulin, and hypercalciuria, 117
protein content, acidosis, and hypercalciuria, 116–117
sodium and hypercalciuria, 118
vitamin D, 118–119
skeletal disease, pre-existing, 114

Obesity, and TC, TG, and LP distribution in children, 415–417
Oncogenes and growth factors, **479–493**
in normal thyroid, 480–484
epidermal growth factor, 482
insulinlike growth factors, 481
oncogenes, 483–484
thyrotropin, 480–481
transforming growth factor beta, 482
and thyroid carcinomas, 469–470, 484–487
growth factors and growth factor receptors, 487–488
medullary, 487
papillary and follicular, 484–486
*C-erbB*, 486
*c-myc/c-fos*, 484–485
*C-ras*, 485–486
tissue-specific oncogenes, 486
and thyroid disease, 484
viruses and oncogenes, 479–480
Oral contraceptives, cardiovascular risk and cholesterol/lipoproteins, 388–389
lipid and lipoprotein changes, 390–391
Orthopedic surgery, in Paget's disease of bone, 193–200
Osteodystrophy, renal. See *Renal osteodystrophy.*
Osteomalacia, 78–81
bone biopsy, 78
clinical characteristics, 78–79
radiology, 79
treatment, 79–81
Osteoporosis, corticosteroid-induced, **95–111**
epidemiology and natural history, 96–97
glucocorticoids and calcium homeostasis, 100–102
intestinal calcium absorption, 100–101
parathyroid activity, 101
urinary calcium excretion, 101–102
pathogenesis, 97–100
glucocorticoid effects on bone cells and remodeling, 97–100
turnover of bone, 100
treatment, 102–106
bone resorption and turnover, 105–106
bone stimulation, 106
calcium and vitamin D supplementation, 104–105
glucocorticoid dosage, 103–104
vertebral, bone GLA-protein in, 5
Oxalate, dietary, and calcium oxalate nephrolithiasis, and enteric hyperoxaluria, 812–813
See also *Hyperoxaluric syndromes.*

Paget's disease of bone, **175–202**

Paget's disease of bone *(Continued)*
clinical presentation, 178–181
arthritis, 181
back pain, 178–179
bone pain, 180–181
etiology, 176–177
history, 175–176
laboratory tests, 183–187
histology, 184–187
patient distribution, 177–178
radiology, 182–183
treatment, 187–200
indications, 188
modalities of, 189–193
orthopedic surgical procedures, 193–200
elective surgery, 196–200
fracture management, 193–196
therapeutic agents, 188–189
tumors, 200
Pain, in distant metastases, 708
Papillary thyroid carcinoma, **545–576**
oncogenes in, 484–486
patient and tumor characteristics, 546–548
age and sex, 546
prior or coexisting thyroid disease, 546–547
surgical pathology, 548
tumor extent, 547–548
prediction of outcome, 549–563
age and sex, 553–554
cause-specific mortality, 553
distant metastases, 551–552
distant metastases and local invasion, 555
DNA ploidy, 561–563
local recurrences, 551
minor prognostic factors, 558
postoperative metastatic nodes, 550–551
postoperative tumor recurrence, 549–550
scoring, staging, and risk groups, 558–561
tumor extent and nodal status, 556–557
tumor size and grade, 554–555
radioiodine therapy, 686–688
surgery for, 666–670
therapy, 563–570
postoperative radioiodine remnant ablation, 565–570
primary surgical resection, 563–565
Parathyroid gland, and medullary thyroid carcinoma, 620, 625–626
and radioiodine therapy, 705–706
See also *Hyperparathyroidism, and renal stones.*
Parathyroid hormone, in corticosteroid-induced osteoporosis, 101
in renal failure, 69–70
in thyroid disorders, 48
Peptides, procollagen I extension, 8–9
Percutaneous stone removal, 923–924
pH, and calcium oxalate urolithiasis, 942
Pheochromocytoma, in MEN 2A, 620, 625–626
Phosphate homeostasis, 47–48
intestinal absorption, 47
renal excretion and handling, 47–48
serum phosphorus, 47
Phospholipids in lipoproteins, 212
Phosphorus, and parenteral nutrition-related bone disease, 115
in renal osteodystrophy, 71–72
Physical activity, and dyslipoproteinemia in children, 415–417, 434
Plasma, oxalate measurement, 853
Pneumonitis, radiation, 704
Polypeptide growth factors, in normal thyroid, 480–483
Population-based studies, of radiation-induced thyroid tumors, 497–501
Pregnancy, coronary heart disease, 387–388
lipids and lipoproteins, 384–387
and radioiodine therapy, 709–710
Probucol, for dyslipoproteinemia, 356–357
Procollagen I extension peptides, and bone formation, 8–9
Progestogens, cardiovascular risk and cholesterol/lipoproteins, 389–390
Prognostic scoring systems, for thyroid carcinoma, 474
Progressive diaphyseal dysplasia (Camurati-Engelmann disease), 158–162
clinical presentation, 158–159
etiology and pathogenesis, 160–162
histopathology, 160
radiology, 159
treatment, 162
Protein, dietary, and clinical studies of renal stones, 807–808
and hypercalciuria, 808–810
GLA. See *GLA-protein.*
and parenteral nutrition-related bone disease, 116–117
Puberty, and TC, TG, and LP distribution in children, 413–414
Pulmonary metastases, in thyroid carcinoma, 698
Purine metabolism, and urinary calculi, **821–838**
degradation to uric acid, 824–826
diagnosis, 831–832
elimination of uric acid, 826–827
medical treatment, 832–834
purine de novo synthesis, 823–824
risk factors, 827–829
salvage pathway, 824
uric acid metabolism, 822
APRT deficiency, 830
HPRT deficiency, 829–830

xanthine oxidase deficiency, 830–831
Pyridoxine deficiency, and hyperoxaluria, 860–861

Quality of life, and radioiodine therapy, 754

Race, and TC, TG, and LP distribution in children, 413
Radiation, ionizing, for childhood thyroid cancer, 652–653
safety of, 711–712
and thyroid cancer, 470–472
Radiation-induced thyroid tumors, **495–508**
clinical management of patients, 501–506
follow-up evaluation, 505–506
radiation to head or neck area, 501–504
therapy, 505
thyroid nodules, 504–505
population-based studies, 497–501
relationship between radiation and thyroid cancer, 495–497
Radiography, of childhood thyroid cancer, 659–660
imaging of thyroid carcinoma, 538–540
Radioiodine therapy, for childhood thyroid cancer, 654–655
for localized thyroid cancer, **741–760**
decision analytic model, 747–748
radioactive iodine, 744–747
leukemia risk and mortality, 746–747
relapse rate, 744–746
results, 749–755
baseline, 749–750
follicular carcinoma, 752–754
men, 752
quality of life, 754
sensitivity analysis, 750–752
tradeoffs, 754–755
and thyroglobulin measurement, 723–724
thyroid carcinoma, 742–744
relapse rate, 742–743
survival after relapse, 743–744
of metastatic thyroid cancer, **685–718**
definitions, 685–686
follow-up evaluations, 711
metastatic disease in papillary and follicular cancer, 686–688
patient preparation, 688–692
laxatives, 692
lithium, 691–692
low-iodine diet, 690–691
thiourea compounds, 688–689
thyroid-stimulating hormone and thyrotropin-releasing hormone, 689–690
radiation safety, 711–712
and residual, recurrent, or metastatic disease, 698–702
side effects and complications, 702–711
anaplastic transformation of well differentiated cancer, 705
blood and bone marrow, 702–704
central nervous system metastases, 707–708
gastrointestinal symptoms, 705
gonadal and genetic effects, 708–711
pain in distant metastases, 708
parathyroid function, 705–706
radiation pneumonitis, 704
salivary glands, 706–707
solid cancer development, 704–705
thyroid storm, 707
vocal cord function, 707
techniques, 695–698
artifacts, 697–698
dosimetric studies, 695–697
pulmonary and skeletal metastases, 698
whole body scanning, 692–695, 729–730
equipment, 695
iodine amounts, 692–695
for papillary thyroid carcinoma, 565–570
Radiology, of carbonic anhydrase II deficiency, 154
of fibrodysplasia ossificans progressiva, 163–165
in hyperparathyroid bone disease, 75–76
of osteogenesis imperfecta, 144–145
in osteomalacia, 79
of osteopetrosis, 149–150
of Paget's disease of bone, 182–183
of pycnodysostosis, 156–157
in renal failure, 73
Radiolucent renal stones, clinical evaluation, 796–797
Radiotherapy, external, 732–733
Rate-dependent renal tubular acidosis, 875
Red blood cells, oxalate absorption and transport, 859–860
Relapse rate, and radioiodine therapy, 742–743, 744–746, 757
Remnant ablation of thyroid carcinoma, follicular, 580–581
papillary, 565–570
Remodeling, bone in normal adult, 24–25
activation, 37–38
bone mass changes, 38
coupling, 38
glucocorticoid effects, 97–100
Renal failure, and acquired hyperlipidemia, 265
Renal osteodystrophy, **65–93**
aluminum metabolism, 67–69
biochemical tests of renal failure, 69–74

Renal osteodystrophy *(Continued)*
alkaline phosphatase, 72
aluminum, 70
bone GLA protein, 72–73
calcium, 71
parathyroid hormone levels, 69–70
phosphorus, 71–72
roentgenography, 73
subtypes, 74
vitamin D metabolites, 72
dialysis arthropathy, chronic, 85–86
erosive spondyloarthropathy, 85–86
hyperparathyroid bone disease, 74–77
bone biopsy, 74
clinical findings, 74–75
roentgenography, 75–76
treatment options, 76–77
low-turnover bone disease, 82–83
mild uremic bone disease, 83–84
mineral metabolism, 66–67
mixed uremic bone disease, 81–82
osteomalacia, 78–81
bone biopsy, 78
clinical characteristics, 78–79
roentgenography, 79
treatment, 79–81
after renal transplantation, 84–85
Renal stones. See *Kidney stones.*
Risk factors, for renal stones, 787–793
hypercalciuria, 787–789
hyperoxaluria, 789–791
hyperuricosuria, 791–792
hypocitraturia, 792–793
for uric acid nephrolithiasis, 827–829
Risk groups, in differentiatied thyroid cancer, 719–720
for papillary thyroid carcinoma, 558–561

Salivary glands, and radioiodine therapy, 706–707
Salvage pathway, in purine metabolism, 824
Sarcoidosis, and renal stones, 844–845
Saturation states, of renal stones, 767–768
Scoring, of papillary thyroid carcinoma, 558–561
Screening programs, cholesterol in elderly, 454–456
dyslipoproteinemia in children, 418–425
for medullary thyroid carcinoma, 627–628
for MEN 2A and 2B, 624–626
triglyceride abnormalities, 318–319
Secretory renal tubular acidosis, 873–874
Sensitivity analysis, of radioiodine therapy, 750–752
Sex of patient, and papillary thyroid carcinoma, 546, 553–554
and thyrotoxicosis, 603–604
Sex hormones, and TC, TG, and LP distribution in children, 413–414
Shock wave lithotripsy, 921–923
Skeleton, in thyroid disorders, 37–45
bone markers, 42–44
hyper- and hypothyroidism, cortical bone, 41–42
trabelcular bone, 39–41
mechanisms of action of thyroid hormones, 44–45
metastases, in thyroid carcinoma, 698
normal bone remodeling, 37–38
Sodium, dietary, and hypercalciuria, 810–812
and parenteral nutrition-related bone disease, 118
Solutions and solute, and renal stones, **767–772**
crystals, formation of, 768–769
modifiers of, 770–771
retention of, 769–770
saturation states, 767–768
Solvents, stone, 911
Spondyloarthropathy, erosive, 85–86
Staghorn calculi, 930
Staging, of papillary thyroid carcinoma, 558–561
Stones, renal. See *Kidney stones.*
Surgery, for nephrolithiasis, **919–935**
background, 919–924
percutaneous stone removal, 923–924
shock wave lithotripsy, 921–923
ureteroscopy, 919–920
clinical factors, 924–925
indications for stone removal, 924
parameters affecting treatment, 925–934
anatomy, 925–926
bladder stones, 932
complications, 933–934
composition of stone, 928–930
obstruction, 926–927
staghorn calculi, 930
stone position, 927–928
stone size, 927
surgery, 932–933
ureteral stones, 930–931
lower, 931–932
mid, 931
upper, 931
for thyroid carcinoma, 473–474, **663–683**, 731–732
for childhood thyroid cancer, 654
for follicular thyroid carcinoma, 580
future of, 676
indications for, 665–666
lymphoma and other rare tumors, 672–673
medullary thyroid carcinoma, 626–627, 671–672
nodule evaluation, 664–665

for papillary thyroid carcinoma, 563–565
postoperative care, 675–676
technical considerations and complications, 673–675
for thyroid carcinoma, 473–474, 731–732
undifferentiated cancer, 672
well differentiated cancers, 666–671
lymphatic spread, 670–671
papillary and follicular, 666–670
occult, 666
Surgical pathology, of papillary thyroid carcinoma, 548
of thyroid nodules, **509–522**
discussion, 519–521
material and methods, 510–511
results, 511–519
Survival after thyroid carcinoma, 628–629, 743–744, 758

$^{99m}$ Technetium, 523–530
$^{201}$ Thallium, 534
Thermography, 540–541
Thiourea compounds, 688–689
Thyroglobulin, in differentiated thyroid carcinoma, 721–726
Thyroid carcinoma, **469–766**
in childhood, **649–662**
clinical presentation, 650
etiology, 652–654
incidence, 650
medullary thyroid carcinoma, 657–658
neck mass assessment, 658–660
prognosis, 655–656
therapy, 654–655
follicular and Hürthle cell, **577–591**
follicular, 577–583
Hürthle cell, 583–577
imaging tests, **523–543**
angiography, 540
computed tomography, 538
dimercaptosuccinic acid, 535
gallium, 536
iodine scanning, 530–533
magnetic resonance imaging, 538
meta-iodobenzylguanidine, 533
nuclear angiography, 536
radiography, 538–540
$^{99m}$technetium, 523–530
$^{201}$thallium, 534
thermography, 540–541
tomography, 535–536
ultrasound, 536–537
xeroradiography, 540
x-ray fluorescent scanning, 537–538
management of differentiated cancer, **719–739**
chemotherapy, 733–734
external radiotherapy, 732–733
imaging techniques, 730–731
risk groups, 719–720
surgery, 731–732
thyroglobulin measurements, 721–726
thyroid hormone suppression, 720–721
total body radioiodine scans and radioiodine therapy, 729–730
ultrasound and fine needle aspiration, 726–729
medullary, **613–635**
anatomy and histology, 613–614
clinical course after thyroidectomy, 627–630
clinical syndromes, 618–621
CT gene expression, 614–616
MEN 2B, 621–623
molecular mechanisms for development of, 623–624
pathology, 617–618
screening for MAN 2A and 2B, 624–626
oncogenes and growth factors, **479–493**
growth factors and growth factor receptors, 487–488
in normal thyroid, 480–484
and thyroid carcinomas, 484–487
and thyroid disease, 484
viruses and oncogenes, 479–480
papillary, **545–576**
patient and tumor characteristics, 546–548
prediction of outcome, 549–563
therapy, 563–570
progress in, **469–478**
diagnosis, 472–473
etiology, 469–472
goals for future, 476–477
management, 473–476
radiation-induced tumors, **495–508**
clinical management of patients, 501–506
population-based studies, 497–501
radiation and thyroid cancer, 495–497
radioiodine therapy, **685–718**
definitions, 685–686
follow-up evaluations, 711
for localized cancer, **741–760**
data, 742–747
decision analytic model, 747–748
results, 749–755
metastatic disease, 686–688
patient preparation, 688–692
radiation safety, 711–712
and residual, recurrent, or metastatic disease, 698–702
side effects and complications, 702–711
techniques, 695–698
whole body scanning, 692–695
surgery, **663–683**

Thyroid carcinoma *(Continued)*
future of, 676
indications for, 665–666
lymphomas and other rare tumors, 672–673
medullary thyroid carcinoma, 671–672
nodule evaluation, 664–665
postoperative care, 675–676
technical considerations and complications, 673–675
undifferentiated cancer, 672
well differentiated cancers, 666–671
surgical pathology of nodules, **509–522**
discussion, 519–521
material and methods, 510–511
results, 511–519
thyrotoxicosis, **593–612**
age and sex distribution, 603–604
clinical findings, 604
gonadal and trophoblastic tumors, 599–600
histopathology, 603
incidental carcinoma, 593–599
laboratory findings, 604–605
metastatic disease, 599, 605–607
outcome, 608–609
therapy, 607–608
well-differentiated thyroid cancer, 600–603
uncommon types, **637–648**
anaplastic carcinoma, 637–642
lymphomas, 642–645
other rare tumors, 645
pathology, 642–643
Thyroid hormones, and bone and mineral metabolism, **35–63**
bone and mineral metabolism, 50–51
calcitropic hormones, 48–50
calcitonin, 50
parathyroid hormone, 48
vitamin D metabolites, 48–50
calcium homeostasis in thyroid disorders, 35–37, 45–46
intestinal absorption, 45
renal calcium excretion, 46
serum calcium, 45–46
clinical aspects, 52–56
bone loss, antithyroid treatment, 55
beta-receptor blocking agents, 55
in subclinical hyperthyroidism, 54
hypercalcemia of hyperthyroidism, 52
hyperthyroid bone disease, 52–54
hypothyroid growth retardation, 52
replacement therapy in hypothyroidism, 54–55
skeleton in thyroid disorders, 37–45
bone markers, 42–44
hyper- and hypothyroidism, cortical bone in, 41–42
trabecular bone in, 39–41
mechanisms of action, 44–45
normal bone remodeling, 37–38
activation, 37–38
bone mass changes, 38
coupling, 38
Thyroid storm, and radioiodine therapy, 707
Thyroid-stimulating hormone, and radioiodine therapy, 689–690
Thyroidectomy, for medullary thyroid carcinoma, 627–630
Thyroiditis, and childhood thyroid cancer, 653–654
Thyrotoxicosis, **593–612**
age and sex distribution, 603–604
clinical findings, 604
from gonadal and trophoblastic tumors, 599–600
from metastatic cancer, 599, 605–607
histopathology, 603
laboratory findings, 604–605
outcome, 608–609
therapy, 607–608
and thyroid carcinoma, incidental, 593–599
well differentiated, 600–603
Thyrotropin, in normal thyroid, 480–481
suppression, 720–721
Thyrotropin-releasing hormone, and radioiodine therapy, 689–690
Tomography, imaging of thyroid carcinoma, 535–536
Transforming growth factor beta, 482
Transplantation, marrow, in osteopetrosis, 152–153
renal, and acquired hyperlipidemia, 267
bone disease after, 84–85
Transport, in cystinuria, intestinal, 890–891
renal, 889–890
of lipids, endogenous, 218–227
exogenous, 216–218
inherited disorders. See *Inherited disorders of lipid transport.*
of lipoproteins, and acquired hyperlipidemia, 260–261
of oxalate, 855–860
Triglycerides, in children, 404–418
and coronary artery disease, **299–309**
epidemiology, 299–302
inherited disorders, 302–303
intervention studies, 303–305
and coronary heart disease, 289–290
in lipoproteins, 209
screening tests, 318–319
TSH suppression, in childhood thyroid cancer, 655
Tumors, gonadal and trophoblastic, thyrotoxicosis from, 599–600
malignant, and renal stones, 846
in Paget's disease of bone, 200
See also *Papillary thyroid carcinoma.*

Ultrasonography, of thyroid carcinoma, 536–537, 726–729
Urease inhibitors, for infection stones, 911
Ureteral stones, 930–931
Ureteroscopy, 919–920
Uric acid renal stones, clinical evaluation, 796–797
  dietary factors, 815–816
  See also *Purine metabolism, and urinary calculi.*
Urine, oxalate measurement, 852–853
  volume in calcium oxalate urolithiasis, 938–939
Urolithiasis, secondary, 909–918
  cystic disorders, 913–914
    urinary diversion, 914
  drug-induced, 914–916
  foreign bodies, 916
  infection stones, 909–911
    pathophysiology, 909–910
    treatment, 910–911
  structural abnormalities, 911–913
    horseshoe kidney, 912–913

Vertebral osteoporosis, bone GLA-protein in, 5
Viruses, and oncogenes, 479–480
Vitamin D, metabolites, in renal osteodystrophy, 72
  in thyroid disorders, 48–50
  in parenteral nutrition-related bone disease, 118–119
  supplementation, in corticosteroid-induced osteoporosis, 104–105
VLDL hyperlipoproteinemia, inherited disorders, 242–243
Vocal cord function, 707
Voltage-dependent renal tubular acidosis, 874–875

Whole body scanning for metastatic disease, 692–695
  and radioiodine therapy, 729–730
Women, cholesterol levels, and coronary heart disease, 289
  dyslipoproteinemia in. See *Dyslipoproteinemia, in women.*

Xanthine oxidase deficiency, and urolithiasis, 830–831
Xeroradiography, 540
X-ray fluorescent scanning, of thyroid carcinoma, 537–538